novo nordisk stock - Search News

Novo Nordisk Skeptic Finally Upgrades Stock

Yahoo Finance · 9h

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.Most Read from BloombergTrump DEI Purge Hits Afforda

Markets Insider · 5h

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Seeking Alpha on MSN · 8h

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

The Motley Fool on MSN · 1d

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 10.22%) and Roche Holdings ( RHHBY 3.62%), up 11.3% and 4%, respectively, through 10:05 a.m. ET today, are behind it.

Markets Insider · 13h

Novo Nordisk upgraded to Buy from Hold at Kepler Cheuvreux

Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s

Roche, Obesity and Novo Nordisk

The Wall Street Journal · 2d

Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more:

Zacks.com on MSN · 5h

NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide.

Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%

Roche is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma , the companies announced Wednesday. The deal would

5h

Wall Street's Biggest Novo Nordisk Bear Just Flipped--Here's Why He Says It's Time to Buy

After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.

3don MSN

Why Novo Nordisk Stock Is Falling Today

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m. ET and was down as ...

2h

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

3don MSN

Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

2d

Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results